Cipla
HC backs Novartis, bars Cipla from selling lung drug copy
By By Jagdeep Worah | 10 Jan 2015
In a blow to those suffering from lung and respiratory diseases, the Delhi High Court on Friday restrained domestic firm Cipla from marketing its affordable generic version of respiratory drug Onbrez, ruling in favour of multinational Novartis
Cipla wants Novartis’s patents on respiratory drug revoked
30 Oct 2014
Cipla, which launched a generic version of the drug, said Novartis imports "negligible quantity" of its patented drug Onbrez from Switzerland, thereby creating a supply shortage at a time when 15 million Indians needed treatment for chronic obstructive pulmonary disease
Cipla to acquire 51% stake in Yemeni pharma firm
30 Jun 2014
Cipla buys 14.6% stake in Chase Pharma to support Alzheimer treatment
12 May 2014
The disease costs the US alone $203 billion annually with projections to reach $1.2 trillion by 2050
Cipla chief Hamied calls for mechanism to make essential drugs affordable
05 May 2014
Cipla chairman Yusuf Hamied has long battled global pharmaceutical majors to ensure that the poor have access to life-saving drugs
